Do analysts prefer CRMD or MENS?

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 80.72%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, CRMD or MENS?

CorMedix has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 2.08 $163.05M $2.14 3.88 Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts rate MENS or TLRY?

Tilray Brands has a consensus target price of $8.00, indicating a potential upside of 74.29%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tilray Brands 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43

Which has better valuation & earnings, MENS or TLRY?

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Tilray Brands $915.45M 0.68 -$121.40M -$1.08 N/A

Do analysts rate MENS or CTNM?

Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 18.77%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, MENS or CTNM?

Jyong Biotech has higher earnings, but lower revenue than Contineum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Contineum Therapeutics $50M 12.83 -$59.98M -$1.73 N/A

Is MENS or CTNM more profitable?

Jyong Biotech's return on equity of 0.00% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Contineum Therapeutics N/A -24.73% -23.51%

Which has better valuation and earnings, AQST or MENS?

Jyong Biotech has lower revenue, but higher earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aquestive Therapeutics $44.54M 14.15 -$83.78M -$0.65 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is AQST or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -144.63% N/A -52.40% Jyong Biotech N/A N/A N/A

Do analysts recommend MENS or EOLS?

Evolus has a consensus target price of $14.50, indicating a potential upside of 63.29%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation & earnings, MENS or EOLS?

Jyong Biotech has higher earnings, but lower revenue than Evolus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Evolus $297.18M 1.97 -$51.64M -$0.52 N/A

Is MENS or EOLS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Evolus -10.85% N/A -13.00%

Jyong Biotech (MENS) Competitors

$2.37 +0.07 (+3.04%)

As of 08/28/2026 04:00 PM Eastern

Compare

MENS vs. CRMD, TLRY, CTNM, AQST, and EOLS

Should you buy Jyong Biotech stock or one of its competitors? Jyong Biotech's main competitors and comparable companies include CorMedix (CRMD), Tilray Brands (TLRY), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), and Evolus (EOLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jyong Biotech compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

CorMedix has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

34.2% of CorMedix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CorMedix and CorMedix both had 1 articles in the media. Jyong Biotech's average media sentiment score of 1.89 beat CorMedix's score of 0.94 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Positive
Jyong Biotech	Very Positive

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 80.72%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CorMedix has a net margin of 40.49% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 40.52% beat Jyong Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Jyong Biotech	N/A	N/A	N/A

Summary

CorMedix beats Jyong Biotech on 10 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Tilray Brands?

Jyong Biotech (NASDAQ:MENS) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Tilray Brands	$915.45M	0.68	-$121.40M	-$1.08	N/A

Jyong Biotech has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Jyong Biotech's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Tilray Brands	-13.11%	-7.76%	-5.59%

Jyong Biotech has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Tilray Brands has a consensus target price of $8.00, indicating a potential upside of 74.29%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

9.4% of Tilray Brands shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tilray Brands had 14 more articles in the media than Jyong Biotech. MarketBeat recorded 15 mentions for Tilray Brands and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Tilray Brands' score of 0.56 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Tilray Brands	Positive

Summary

Tilray Brands beats Jyong Biotech on 8 of the 14 factors compared between the two stocks.

How does Jyong Biotech compare to Contineum Therapeutics?

Jyong Biotech (NASDAQ:MENS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Jyong Biotech has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Contineum Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 18.77%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Contineum Therapeutics had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Contineum Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Contineum Therapeutics' score of 0.43 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Contineum Therapeutics	Neutral

Jyong Biotech has higher earnings, but lower revenue than Contineum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Contineum Therapeutics	$50M	12.83	-$59.98M	-$1.73	N/A

Jyong Biotech's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Contineum Therapeutics	N/A	-24.73%	-23.51%

Summary

Jyong Biotech and Contineum Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Jyong Biotech compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Aquestive Therapeutics presently has a consensus target price of $8.80, suggesting a potential upside of 75.30%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aquestive Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aquestive Therapeutics had 17 more articles in the media than Jyong Biotech. MarketBeat recorded 18 mentions for Aquestive Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Aquestive Therapeutics' score of 0.92 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aquestive Therapeutics	Positive
Jyong Biotech	Very Positive

Aquestive Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

Jyong Biotech has lower revenue, but higher earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	14.15	-$83.78M	-$0.65	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Jyong Biotech	N/A	N/A	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aquestive Therapeutics beats Jyong Biotech on 8 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Evolus?

Jyong Biotech (NASDAQ:MENS) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Evolus has a consensus target price of $14.50, indicating a potential upside of 63.29%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Evolus has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Jyong Biotech has a net margin of 0.00% compared to Evolus' net margin of -10.85%.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Evolus	-10.85%	N/A	-13.00%

In the previous week, Evolus had 9 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Evolus and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Evolus' score of 0.86 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Evolus	Positive

Jyong Biotech has higher earnings, but lower revenue than Evolus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Evolus	$297.18M	1.97	-$51.64M	-$0.52	N/A

90.7% of Evolus shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Evolus beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MENS vs. The Competition

Export

Metric	Jyong Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$174.86M	$12.21B	$7.24B	$12.93B
Dividend Yield	N/A	2.62%	2.54%	11.02%
P/E Ratio	N/A	780.29	271.50	25.41
Price / Sales	N/A	756.07	624.06	97.19
Price / Cash	N/A	95.73	79.29	54.21
Price / Book	-7.18	11.93	12.95	6.14
Net Income	-$4.67M	$2.81B	$3.46B	$347.93M
7 Day Performance	8.72%	0.52%	-0.11%	-0.78%
1 Month Performance	5.80%	6.37%	8.32%	5.60%
1 Year Performance	-95.68%	6.09%	24.64%	15.64%

Jyong Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MENS Jyong Biotech	N/A	$2.37 +3.0%	N/A	-95.7%	$174.86M	N/A	N/A	31	Positive News
CRMD CorMedix	2.1764 of 5 stars	$8.55 +3.2%	$15.00 +75.5%	-42.2%	$666.03M	$457.20M	3.99	30
TLRY Tilray Brands	4.0475 of 5 stars	$4.88 +3.5%	$8.00 +63.8%	-68.8%	$665.07M	$915.45M	N/A	3,595
CTNM Contineum Therapeutics	1.8424 of 5 stars	$17.05 +2.5%	$20.25 +18.8%	+69.7%	$641.23M	$50M	N/A	31
AQST Aquestive Therapeutics	2.4349 of 5 stars	$5.09 +5.9%	$8.80 +73.1%	+31.1%	$638.22M	$44.54M	N/A	160	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jyong Biotech (MENS) Competitors

MENS vs. CRMD, TLRY, CTNM, AQST, and EOLS

How does Jyong Biotech compare to CorMedix?

Summary

How does Jyong Biotech compare to Tilray Brands?

Summary

How does Jyong Biotech compare to Contineum Therapeutics?

Summary

How does Jyong Biotech compare to Aquestive Therapeutics?

Summary

How does Jyong Biotech compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jyong Biotech (MENS) Competitors

MENS vs. CRMD, TLRY, CTNM, AQST, and EOLS

How does Jyong Biotech compare to CorMedix?

Which has more volatility & risk, CRMD or MENS?

Which has higher valuation and earnings, CRMD or MENS?

Do institutionals and insiders have more ownership in CRMD or MENS?

Does the media refer more to CRMD or MENS?

Do analysts prefer CRMD or MENS?

Is CRMD or MENS more profitable?

Summary

How does Jyong Biotech compare to Tilray Brands?

Which has better valuation & earnings, MENS or TLRY?

Is MENS or TLRY more profitable?

Which has more risk and volatility, MENS or TLRY?

Do analysts rate MENS or TLRY?

Do institutionals & insiders hold more shares of MENS or TLRY?

Does the media favor MENS or TLRY?

Summary

How does Jyong Biotech compare to Contineum Therapeutics?

Which has more volatility & risk, MENS or CTNM?

Do analysts rate MENS or CTNM?

Does the media refer more to MENS or CTNM?

Which has stronger valuation & earnings, MENS or CTNM?

Is MENS or CTNM more profitable?

Summary

How does Jyong Biotech compare to Aquestive Therapeutics?

Do analysts rate AQST or MENS?

Does the media refer more to AQST or MENS?

Which has more volatility & risk, AQST or MENS?

Which has better valuation and earnings, AQST or MENS?

Is AQST or MENS more profitable?

Do insiders and institutionals believe in AQST or MENS?

Summary

How does Jyong Biotech compare to Evolus?

Do analysts recommend MENS or EOLS?

Which has more volatility & risk, MENS or EOLS?

Is MENS or EOLS more profitable?

Does the media prefer MENS or EOLS?

Which has better valuation & earnings, MENS or EOLS?

Do institutionals & insiders have more ownership in MENS or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools